Curie: The Oncology Brief

Radiation Oncology Consolidation, Neuropathy Prevention, and New Immunotherapy for HCC

Love what you hear? Download the Curie app from the App Store today [https://curie.md/app.html?utm_source=podcastplatforms&utm_medium=social&utm_campaign=normal&utm_term=doctors&utm_content=podcast]. Curie is your personalized, expert-driven healthcare podcast platform—offering in-depth analysis, timely insights, and discussions tailored for medical professionals. In this episode of Curie, Matt covers three key updates in oncology. A new analysis shows that radiation oncology practices are consolidating rapidly, raising concerns about access to care, patient choice, and job stability for oncologists. In breast cancer, a randomized trial finds that hand cooling and compression can significantly reduce chemotherapy-induced neuropathy, offering a simple, cost-effective strategy to protect patients’ nerves. And finally, the EMA has recommended expanding nivolumab plus ipilimumab for advanced hepatocellular carcinoma, positioning it as an alternative to the current standard of care. Tune in for the latest insights shaping cancer treatment.

MRD in AML, Early-Phase Cancer Trials Reality Check, and the Hospital-at-Home Debate

Love what you hear? Download the Curie app from the App Store today [https://curie.md/app.html?utm_source=podcastplatforms&utm_medium=social&utm_campaign=normal&utm_term=doctors&utm_content=podcast]. Curie is your personalized, expert-driven healthcare podcast platform—offering in-depth analysis, timely insights, and discussions tailored for medical professionals. In this episode of Curie, Matt covers three important topics shaping cancer care. A new study confirms that achieving MRD negativity early in AML is critical for long-term survival, reinforcing MRD’s growing role in treatment decisions. We then explore the hard truth about early-phase cancer trials, revealing that only 16.2% of phase 2 treatments ever gain FDA approval—what does this mean for patients enrolling in these studies? Finally, we examine the rapid expansion of Hospital-at-Home care, a model that could change oncology treatment, but also raises concerns about patient safety and healthcare equity. Tune in for the latest updates and insights.

Datopotamab Deruxtecan Approved, Immunotherapy Timing, and Rising Early-Onset Colorectal Cancer

In this episode of Curie, Matt covers three major developments in oncology. The FDA has approved datopotamab deruxtecan (Datroway) for HR positive, HER2 negative breast cancer, marking a new era for antibody-drug conjugates in this disease. A meta-analysis suggests that the timing of immunotherapy infusions may impact survival outcomes, raising questions about how circadian rhythms influence treatment response. Finally, a global analysis confirms that early-onset colorectal cancer is on the rise worldwide, challenging current screening guidelines and prompting discussions on prevention strategies. Tune in for the latest insights shaping cancer care.

ASCO Ovarian Cancer Guidelines, Mammo-50 Breast Cancer Surveillance, and NRG1 Fusion Therapy Advances

In this episode of Curie, Matt breaks down three major updates in oncology. ASCO has released updated guidelines for advanced ovarian cancer, emphasizing primary cytoreductive surgery over neoadjuvant chemotherapy when feasible. The Mammo-50 trial challenges the standard of annual mammographic surveillance for breast cancer survivors over 50, showing that less frequent screening is non-inferior. Finally, the eNRGy trial confirms the efficacy of zenocutuzumab in treating NRG1 fusion-positive cancers, a rare but actionable oncogenic driver in NSCLC and pancreatic cancer. Tune in for expert insights into how these findings are shaping cancer care.

New Approvals in Oncology: Vimseltinib for TGCT, Sotorasib for KRAS G12C CRC, and Immunotherapy in ER Positive Breast Cancer

Love what you hear? Download the Curie app from the App Store today [https://curie.md/app.html?utm_source=podcastplatforms&utm_medium=social&utm_campaign=normal&utm_term=doctors&utm_content=podcast]. Curie is your personalized, expert-driven healthcare podcast platform—offering in-depth analysis, timely insights, and discussions tailored for medical professionals. In this episode of Curie, Matt covers three major updates in oncology. Vimseltinib (Romvimza) has been FDA-approved for tenosynovial giant cell tumors (TGCT), providing a new non-surgical option for symptomatic patients. Sotorasib plus panitumumab is now approved for KRAS G12C-mutated colorectal cancer, marking a breakthrough in targeted therapy for this hard-to-treat population. Finally, two phase III trials show that adding immunotherapy to neoadjuvant chemotherapy improves pathological complete response rates in high risk ER positive, HER2 negative breast cancer—a potential paradigm shift in treatment. Tune in for the latest updates in precision oncology!